DK1622936T3 - Fremgangsmåde til fremstilling af en N-terminalt modificeret kemotaktisk faktor - Google Patents

Fremgangsmåde til fremstilling af en N-terminalt modificeret kemotaktisk faktor

Info

Publication number
DK1622936T3
DK1622936T3 DK04739081T DK04739081T DK1622936T3 DK 1622936 T3 DK1622936 T3 DK 1622936T3 DK 04739081 T DK04739081 T DK 04739081T DK 04739081 T DK04739081 T DK 04739081T DK 1622936 T3 DK1622936 T3 DK 1622936T3
Authority
DK
Denmark
Prior art keywords
mcp
monocytes
agonist
producing
chemotactic factor
Prior art date
Application number
DK04739081T
Other languages
Danish (da)
English (en)
Inventor
Roman Necina
Randolph Seidler
Martin Lenter
Henri Doods
Robert Wandl
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Application granted granted Critical
Publication of DK1622936T3 publication Critical patent/DK1622936T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Vascular Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK04739081T 2003-05-02 2004-04-13 Fremgangsmåde til fremstilling af en N-terminalt modificeret kemotaktisk faktor DK1622936T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03010014A EP1473304A1 (de) 2003-05-02 2003-05-02 Verfahren zur Herstellung eines N-terminal modifizierten chemotaktischen Faktors
PCT/EP2004/003856 WO2004096850A1 (de) 2003-05-02 2004-04-13 Verfahren zur herstellung eines n-terminal modifizierten chemotaktischen faktors

Publications (1)

Publication Number Publication Date
DK1622936T3 true DK1622936T3 (da) 2008-10-27

Family

ID=32981800

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04739081T DK1622936T3 (da) 2003-05-02 2004-04-13 Fremgangsmåde til fremstilling af en N-terminalt modificeret kemotaktisk faktor

Country Status (20)

Country Link
EP (2) EP1473304A1 (ko)
JP (1) JP2007535891A (ko)
KR (1) KR20050121751A (ko)
CN (1) CN1784420A (ko)
AT (1) ATE398631T1 (ko)
AU (1) AU2004233964A1 (ko)
BR (1) BRPI0410023A (ko)
CA (1) CA2524270A1 (ko)
CO (1) CO5640145A2 (ko)
DE (1) DE502004007394D1 (ko)
DK (1) DK1622936T3 (ko)
ES (1) ES2309528T3 (ko)
MX (1) MXPA05011700A (ko)
PL (1) PL1622936T3 (ko)
PT (1) PT1622936E (ko)
RU (1) RU2005137356A (ko)
SI (1) SI1622936T1 (ko)
UA (1) UA83661C2 (ko)
WO (1) WO2004096850A1 (ko)
ZA (1) ZA200507702B (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008002101A (es) 2005-08-12 2008-04-19 Schering Corp Fusiones de la proteina-1 quimiotactica de monocito.
US8524217B2 (en) 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92937A0 (en) * 1989-01-31 1990-09-17 Us Health Human derived monocyte attracting protein,pharmaceutical compositions comprising it and dna encoding it
US6869924B1 (en) * 1989-01-31 2005-03-22 The United States Of America As Represented By The Department Of Health And Human Services Human derived monocyte attracting purified protein product useful in a method of treating infection and neoplasms in a human body, and the cloning of full length cDNA thereof
WO1999005279A1 (en) * 1997-07-25 1999-02-04 Zeneca Limited Mcp-1 analogs

Also Published As

Publication number Publication date
EP1622936A1 (de) 2006-02-08
DE502004007394D1 (de) 2008-07-31
PT1622936E (pt) 2008-08-08
UA83661C2 (ru) 2008-08-11
ATE398631T1 (de) 2008-07-15
SI1622936T1 (sl) 2008-12-31
EP1473304A1 (de) 2004-11-03
BRPI0410023A (pt) 2006-04-25
RU2005137356A (ru) 2006-06-10
CA2524270A1 (en) 2004-11-11
ES2309528T3 (es) 2008-12-16
ZA200507702B (en) 2007-02-28
MXPA05011700A (es) 2006-01-23
AU2004233964A1 (en) 2004-11-11
CO5640145A2 (es) 2006-05-31
EP1622936B1 (de) 2008-06-18
WO2004096850A1 (de) 2004-11-11
JP2007535891A (ja) 2007-12-13
KR20050121751A (ko) 2005-12-27
CN1784420A (zh) 2006-06-07
PL1622936T3 (pl) 2008-11-28

Similar Documents

Publication Publication Date Title
Eble et al. α2β1 integrin is not recognized by rhodocytin but is the specific, high affinity target of rhodocetin, an RGD-independent disintegrin and potent inhibitor of cell adhesion to collagen
Chen et al. Bone sialoprotein mRNA expression and ultrastructural localization in fetal porcine calvarial bone: comparisons with osteopontin
Ten Hagen et al. Cloning and characterization of a ninth member of the UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase family, ppGaNTase-T9
Shi-wen et al. Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1
Terranova et al. Laminin receptor on human breast carcinoma cells.
Konttinen et al. Increased expression of extracellular matrix metalloproteinase inducer in rheumatoid synovium
Mochizuki et al. IL-4 induces eotaxin: a possible mechanism of selective eosinophil recruitment in helminth infection and atopy
Bannert et al. Sialylated O-glycans and sulfated tyrosines in the NH2-terminal domain of CC chemokine receptor 5 contribute to high affinity binding of chemokines
Yamada Fibronectin peptides in cell migration and wound repair
DE60035356D1 (de) Faktor ix/faktor ixa aktivierende antikörper
SE9500778D0 (sv) Process for producing a protein
ATE413769T1 (de) Sprachsignalverarbeitung für die gemeinsame adaptive reduktion von störgeräuschen und von akustischen echos
Nagakubo et al. A high endothelial venule secretory protein, mac25/angiomodulin, interacts with multiple high endothelial venule-associated molecules including chemokines
DK1476541T3 (da) Cytokin (zcytor17-ligand)
Votta et al. CKβ‐8 [CCL23], a novel CC chemokine, is chemotactic for human osteoclast precursors and is expressed in bone tissues
ATE360689T1 (de) Cxcr3 chemokine rezeptor, antikoerper, nukleinsaeure und deren verfahren zur anwendung
MX2007009466A (es) Anticuerpos monoclonales de anti-interferon alfa y metodos para su uso.
PT1307455E (pt) Inibidores de adesao celular mediada por (alfa)l (beta)2
DK1622936T3 (da) Fremgangsmåde til fremstilling af en N-terminalt modificeret kemotaktisk faktor
Randall Armant Cell interactions with laminin and its proteolytic fragments during outgrowth of mouse primary trophoblast cells
US5652133A (en) Cloning and expression of the human macrophage inflammatory protein-1.alpha.α) /rantes receptor
Kariya et al. Efficient expression system of human recombinant laminin-5
ATE294236T1 (de) Promotor der tie rezeptor protein kinase
Kadoya et al. Laminin α1 chain G domain peptide, RKRLQVQLSIRT, inhibits epithelial branching morphogenesis of cultured embryonic mouse submandibular gland
Wang et al. Glycosylation regulates N-terminal proteolysis and activity of the chemokine CCL14